Summary The concentration of magnesium in serum has been shown to fall to potentially dangerously low levels after several courses of treatment with cis-diamminedichloroplatinum II (cis-platin). The aims of this study were to examine the effects of magnesium supplementation on predicted outcome of treatment, rate of response to treatment and toxicity of treatment. Sixteen patients with testicular cancer were studied in detail over a 14 month period. One patient with an ovarian dysgerminoma was also included in the study. Eight patients were randomised to receive magnesium supplements both intravenous and oral; nine did not.
courses.
The concentration of magnesium in serum may fall to potentially dangerous levels after several courses of treatment with cis-diamminedichloroplatinum (II) (cis-platin) which is used as part of a combination chemotherapeutic regime for teratoma and other tumours (Schilsky & Anderson, 1979; Willox et al., 1981) . There are problems in recognising the clinical symptoms of hypomagnesaemia such as tingling, weakness, lethargy, depression and ataxia since these are not uncommon side-effects of chemotherapy. Suggested causes of the hypomagnesaemia due to cis-platin are the nephrotoxicity of the drug resulting in a specific magnesium-losing renal tubular defect (Schilsky et al., 1982) and the anorexia, nausea, and vomiting produced by cis-platin with consequent reduced intake and loss in vomitus (Ohnuma & Holland, 1977) . In addition to hypomagnesaemia, there may be accompanying hypokalaemia and hypocalcaemia (Stuart-Harris et al., 1980) and this has been seen in a number of our patients.
Parsons et al. (1974) have suggested that magnesium depletion decreases tumour growth and may therefore be beneficial to the host; however our experience, during treatment of patients who have teratoma or ovarian carcinoma with cis-platin, suggests that the low magnesium levels produce potentially serious additional problems. It has been suggested that routine magnesium supplementation become part of cis-platin-containing regimes (Macaulay et al., 1982) , although the value of this approach has not previously been assessed in a randomised fashion. reported by our group (McAllister et al., 1985) . Creatinine clearance and serum creatinine levels showed no significant changes between groups and over the four courses of treatment. Urine magnesium excretion was consistently higher in the supplemented group (mean difference 6.6 mmol 24 h-1), but less than the magnesium supplements given (8mmol 24h-1). Dietary energy intake in both groups showed a progressive fall from day 3 of cis-platin treatment, slowly increasing for 10-12 days following treatment to normal (Figure 2 effects to patients receiving magnesium supplements. Previous studies on our group of cancer patients report a 43% incidence of anorexia (Willox et al., NS 1984) plus a 73% incidence of deficiencies of all P < 0.01 dietary components with a 78% incidence of specific dietary magnesium deficiency in out patients and an 80% incidence in in-patients (Willox, 1984) . A 37% incidence of low serum magnesium levels has been shown in this group (Willox, 1984 damage. Schilsky et al. (1982) have shown prolonged hypomagnesaemia following cis-platin treatment and long term follow up of magnesium supplemented patients in Glasgow will be interesting.
The number of patients included in this study was unfortunately small due to the number of patients referred for chemotherapy and the time available for the study to be performed. As a result it is impossible to assess the effects of supplementation in patients with low and high volume metastases separately. Although magnesium supplementation appears to be beneficial for all patients, it is likely that the greatest benefit will be to patients with large volume metastatic disease who may require prolonged treatment withl cisplatin. Minimising treatment delays and renal damage in these patients is essential.
Magnesium supplementation should however become a routine part of cis-platin therapy. Further studies to examine the best methods of supplementation are indicated.
